Clinical trial NCT00258427: Hematopoietic Stem Cell Transplantation in High Risk Patients With Fanconi Anemia
Official title: Hematopoietic Stem Cell Transplantation in High Risk Patients With Fanconi Anemia MT2002-02
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Fanconi Anemia
Keywords: Fanconi anemia
Lead sponsor: Masonic Cancer Center, University of Minnesota
Sponsor class: OTHER
First posted: 2005-11-24
Enrollment: 14
Sex: ALL
Maximum age (years): 44
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: RATIONALE: A bone marrow or umbilical cord blood transplant may be able to replace blood-forming cells that were destroyed by chemotherapy. Giving combination chemotherapy before a donor stem cell transplant may make the transplant more likely to work. This may be an effective treatment for patients with high risk Fanconi's anemia.

PURPOSE: This clinical trial is studying how well combination chemotherapy works in treating high risk patients who are undergoing a donor stem cell transplant for Fanconi's anemia.

Detailed description: OBJECTIVES:

Primary

* Determine whether the incidence of neutrophil engraftment is acceptable in high-risk patients with Fanconi's anemia treated with busulfan, cyclophosphamide, fludarabine, and antithymocyte globulin followed by allogeneic hematopoietic stem cell transplantation.

Secondary

* Determine the tolerability of mycophenolate mofetil in these patients.
* Determine the incidence of acute and chronic graft-vs-host disease in patients treated with this regimen.
* Determine the incidence of major infections in patients with a history of major infections treated with this regimen.
* Determine the incidence of relapse in patients with refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia treated with this regimen
* Determine the probability of 1-year survival of patients treated with this regimen.

OUTLINE: Patients are stratified according to donor/recipient HLA type (identical vs other).

* Cytoreductive combination chemotherapy: Patients receive busulfan intravenously (IV) over 2 hours twice daily on days -7 and -6 and cyclophosphamide IV over 2 hours and fludarabine IV over 30 minutes once daily on days -5 to -2.
* Graft failure prophylaxis: Patients receive methylprednisolone IV twice daily on days -5 to 30 and anti-thymocyte globulin IV over 4-6 hours twice daily on days -5 to -1.
* Graft-vs-host disease prophylaxis: Patients receive cyclosporine IV over 2 hours twice daily on days -3 to 100 (if patient has a matched sibling donor) or days -3 to 180 (if patient has another donor type). Patients also receive mycophenolate mofetil orally or IV twice daily on days -3 to 45.
* Allogeneic hematopoietic stem cell transplantation (HSCT): Patients undergo allogeneic HSCT (using bone marrow or umbilical cord blood) on day 0. Patients receive filgrastim (G-CSF) subcutaneously beginning on day 1 and continuing until blood counts recover.

After completion of study treatment, patients are followed periodically for 3 years.

Eligibility criteria: Inclusion Criteria:

* Patients must be \<45 years of age with a diagnosis of Fanconi anemia with:

  * Biallelic BRCA2 mutations, or
  * Aplastic anemia, or advanced myelodysplastic syndrome (MDS) (MDS with ≥5% blasts), or acute leukemia who are ineligible for total body irradiation. Aplastic anemia is defined as having at least one of the following (with or without cytogenetic abnormalities): platelet count \<20 \* 10\^9, - absolute neutrophil count (ANC) \<5 \* 10\^8/L, - Hgb \<8 g/dL
* Patients must have an HLA-A, B, DRB1 identical or 1 antigen mismatched related or unrelated BM donor or have an HLA-A, B, DRB1 identical, 1 antigen or 2 antigen mismatched related or unrelated umbilical cord blood (UCB) donor. Patients and donors will be typed for HLA-A and B using serological level typing and for DRB1 using high resolution molecular typing.
* Adequate major organ function including:

  * Cardiac: ejection fraction \>45%
  * Hepatic: no clinical evidence of hepatic failure (e.g. coagulopathy, ascites, no cirrhosis)
  * Karnofsky performance status \>70% or Lansky \>50%
* Women of child bearing potential must be using adequate birth control and have a negative pregnancy test.

Exclusion Criteria:

* Active CNS leukemia at time of HSCT.
* Active uncontrolled infection within one week of hematopoietic stem cell transplant (HSCT).
* Pregnant or lactating female.

Donor Inclusion Criteria:

* Donor must be in good health based on review of systems and results of physical examination.
* Donor must have a normal hemoglobin, white count, platelet count and partial thromboplastin time (PTT), and a negative diepoxybutane (DEB) test.
* HIV-NAT negative, HTLV-1, HTLV-2 negative, Hepatitis B and C negative.
* Female donors of childbearing potential must have a negative pregnancy test.
* Unrelated donors must agree to peripheral blood stem cell (PBSC) donation

Donor Exclusion Criteria:

* Donor is a lactating female.

Primary outcomes:
measure: Number of Participants Experiencing Graft Failure
timeFrame: Day 30
Secondary outcomes:
measure: Number of Participants Experiencing Chronic Graft-Versus-Host Disease
timeFrame: Day 42
measure: Number of Participants Experiencing Chronic Graft-Versus-Host Disease
timeFrame: 1 year
measure: Number of Participants Experiencing Acute Graft-Versus-Host Disease
timeFrame: 1 year
measure: Number of Participants Experiencing Acute Graft-Versus-Host Disease
timeFrame: Day 42
measure: Number of Participants Experiencing Relapse
timeFrame: 1 Year
measure: Number of Participants Experiencing Overall Survival
timeFrame: 1 Year
measure: Number of Participants Experiencing Major Infections
timeFrame: Day 1 through 1 year post-transplant
Other outcomes:
Locations:
city: Minneapolis
country: United States
facility: Masonic Cancer Center, University of Minnesota
state: Minnesota
Study officials:
affiliation: Masonic Cancer Center, University of Minnesota
name: Margaret MacMillan, MD
role: PRINCIPAL_INVESTIGATOR
References: